






Article abstract—The outcome of 34 women with anti-Yo–associated para-
neoplastic cerebellar degeneration was reviewed. Three patients had not de-
veloped cancer after more than 4 years of follow-up. The only independent
predictor for survival was the type of associated tumor (risk ratio, 1.79; 95%
CI, 1.02 to 3.12). Median survival was 100 months for patients with breast
cancer and 22 for those with gynecologic cancer. Although paraneoplastic
cerebellar degeneration leads to the diagnosis of cancer in 63% of the pa-
tients, cancer progression was the cause of death in 52%.
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Previous series and case reports have established the
clinical characteristics and underlying neoplasms of
patients with paraneoplastic cerebellar degeneration
(PCD) associated with anti-Yo antibodies (Yo-Ab).
The consensus is that the predictive value of Yo-Ab
for the diagnosis of an underlying cancer is close to
100% and that patients can be cured from their tu-
mor but remain severely disabled from the PCD.
These assertions have been supported by clinical de-
scriptions, usually with follow-up shorter than 2
years.1-3 In this study, we retrospectively analyzed
the clinical outcome and prognostic factors in a se-
ries of 34 patients with PCD and Yo-Ab who were
followed until death or for a median of 84 months.
Methods. Patients. We selected 34 patients with PCD
and Yo-Ab from whom the following information was avail-
able: neurologic symptoms and degree of disability (Rankin
score [RS]), type and stage of tumor, treatments given for
the cancer and PCD, and cancer and neurologic outcomes.
Follow-up was obtained through telephone calls and mail
contact with the referring physicians. Yo-Ab were detected
by immunohistochemistry on frozen sections of human cer-
ebellum and confirmed by immunoblot of Yo recombinant
protein as previously described.4
All 34 patients were women with a median age of 59
years (range, 29 to 72 years). At a median follow-up of 84
months (range, 16 to 165 months), 11 patients were alive
(6) or lost to follow-up (5). All but five patients with known
cancer received appropriate antineoplastic treatment. Tu-
mor response was evaluated at the end of treatment by the
patient’s oncologist. Five patients were not treated: four
were severely disabled and in one the tumor was diag-
nosed at autopsy. Twenty-three patients (67%) received
immunotherapy: plasmapheresis, immunoglobulins, corti-
costeroids, or cyclophosphamide either alone or in several
combinations. Six patients were treated with chemother-
apy and immunotherapy simultaneously. The neurologic dis-
ability was evaluated by a modified RS as previously
reported.5 No patient improved with treatment of cancer or
immunotherapy.
Statistical analysis. Survival time was determined
from onset of PCD to death. Kaplan-Meier analysis was
used to evaluate survival. Prognostic factors for survival
were analyzed in the group of 25 patients with known
cancer who received standard antineoplastic treatment.
Differences between groups were estimated by log-rank
test. A Cox proportional hazards regression model was
used to verify associations of survival with several vari-
ables: age, tumor type (breast versus gynecologic), RS,
time to reach the worst RS, first clinical diagnosis (PCD or
tumor), and treatment with immunotherapy.
Results. Twenty patients (58.8%) were chairbound (RS
.3) when PCD was diagnosed (median delay of diagnosis,
2 months); eventually, 32 patients (94%) became nonambu-
latory during the course of the disease. The time to reach
the worst RS was less than 4 months in 65% of patients.
Three patients had a less severe PCD and remained ambu-
latory (RS #3) for 8, 19, and 20 months.
Thirty patients had cancer (table 1). All 12 patients
with breast cancer had metastatic lymph nodes at the time
of tumor diagnosis. Two patients with negative mammo-
grams had enlarged axillary lymph nodes that led to the
discovery of the cancer. Fifteen of 18 patients with gyneco-
logic cancer had metastatic disease; only three had a local-
ized ovarian tumor that was detected after the diagnosis of
PCD. Tumor was not found in four patients: one died 8
months after diagnosis of PCD and autopsy was not done,
and the other three are alive with follow-ups of 49, 89, and
96 months.
PCD antedated the diagnosis of the tumor in 19 of 30
patients (63%) by a median of 5 months (range, 0 to 13
months). Five patients developed PCD shortly after start-
ing cancer treatment and six after having completed treat-
ment (median, 22 months; range, 6 to 43 months). One of
these six patients developed PCD before a tumor recur-
rence, another at the time of tumor recurrence, and the
other four died 3, 5, 11, and 15 months after developing
PCD without clinical evidence of tumor relapse; however,
periodic radiologic evaluations were not done and postmor-
tem studies were not granted.
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The median survival of the 34 patients was 22 months
(range, 3 to 164 months). The cause of death was related to
tumor progression in 12 patients and to PCD in nine; and
unknown in two. One patient with radiologic findings sug-
gestive of a gynecologic cancer refused further studies or
treatment and she was lost after a follow-up of 16 months.
In the 25 patients whose cancer was treated, the pa-
tient’s age (60 years or older) and the presence of a gyne-
cologic cancer were significantly associated with a shorter
survival (table 2). The type of tumor was the only indepen-
dent predictive factor for survival with a risk ratio of 1.79
(95% CI, 1.02 to 3.12). Median survival was 100 months for
patients with breast cancer and 22 months for patients
with gynecologic cancer. At the time of the analysis, all 13
patients with gynecologic cancer were dead and cancer
progression was the cause of death in 61%. By contrast, 7
(58%) patients with breast cancer were alive (figure).
Discussion. We examined the long-term outcome
of a series of 34 patients with PCD and Yo-Ab and
found that, contrary to previous statements, the
overall prognosis of the cancer is rather poor, partic-
ularly for patients with gynecologic tumors. Our
finding is probably explained by two features. First,
tumor progression was the main cause of death in
52% of the patients, even though PCD prompted the
search of the tumor in 63% of the cases. Second, 29%
of patients died as a result of the debilitating neuro-
logic condition.
Our failure to cure the cancer in 52% of the pa-
tients is in part due to the fact that at the time of
diagnosis most tumors had already metastasized to
regional lymph nodes or extended beyond the initial
organ. In our patients with gynecologic tumors, the
frequency of limited disease was similar to the 17%
found in a series of 18 patients with PCD and ovar-
ian cancer.6 Although the gynecologic tumors of pa-
tients with PCD may have smaller volumes than
those observed in patients without PCD,6 the detec-
tion of regional metastasis or invasion of local struc-
tures drastically decreases the possibility of tumor
control.7 All our patients with breast cancer had ax-
illary lymph node metastases, a feature that resem-
bles the high frequency of regional (mediastinal)
lymph node involvement in patients with small-cell
lung cancer and anti-Hu–associated syndromes, sug-
gesting that the tumor cells must invade the regional
lymph nodes to trigger the immune response that
causes the paraneoplastic neurologic disorder.8





(n 5 12) Total
Temporal relation between PCD and
tumor diagnosis
PCD . 3 mo before tumor
diagnosis
6 5 11
Simultaneous 8 5 13
PCD . 3 mo after tumor
diagnosis
4 2 6
Staging at tumor diagnosis†
Local 3 0 3
Regional (lymph nodes or
adjacent structures)
7 10 17
Systemic metastases 5 1 6
No tumor 3 1 4
Immunotherapy 13 8 21
Response to tumor treatment
Complete response 5 9 14
Other response 8 2 10
No treatment 5 0 5
Unknown 0 1 1
Median survival, mo 15 100 22
Cause of death
Oncologic 9 3 12
Neurologic 6 2 8
Unknown 2 0 2
* Type of gynecologic cancer: ovary (13), fallopian tube (1), cervix
(1), metastatic adenocarcinoma in the retroperitoneal lymph
nodes (1), and pelvic tumor diagnosed by radiology (2).
† In two of the six patients who developed PCD when the tumor
was in remission, staging refers to the time of tumor relapse.
No tumor relapse was found in the other four patients.
PCD 5 paraneoplastic cerebellar degeneration.
Table 2 Association between clinical characteristics and survival




survival, mo p Value
Age, y
,60 11 29 (12–164) 0.0335
$60 14 15 (3–60)
Tumor type
Ovary 13 22 (3–41) 0.0068
Breast 12 100 (8–164)
Rankin score at
PCD diagnosis
0–3 12 22 (5–60) 0.1483
4–5 13 28 (3–164)
Time to worst
Rankin score, mo
#3 14 26 (8–92) 0.9085
.3 11 15 (3–164)
First event
PCD 14 28 (8–93) 0.1827
Tumor 11 20 (3–164)
Immunotherapy
Yes 19 22 (3–164) 0.3024
No 6 38 (12–93)
PCD 5 paraneoplastic cerebellar degeneration.
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In patients with anti-Hu antibodies and paraneo-
plastic encephalomyelitis, effective treatment of
the tumor appears to correlate with a stabilization of
the neurologic disorder.5 In contrast, although Yo-
Ab–associated symptoms are more restricted to cere-
bellum, the disease has a fast and aggressive course
and most patients become bed bound during the first 3
months after diagnosis. This clinical evolution coupled
with our finding that 37% of the patients developed
PCD when they were on antineoplastic treatments or
when the tumor was in remission suggest that treat-
ment of the tumor alone is not enough to stabilize the
disease at the time the cerebellar dysfunction is not
severe.
Although there is experimental and limited clini-
cal evidence that cytotoxic T lymphocytes may be
responsible for the death of Purkinje cells,9 conven-
tional immunotherapies are not helpful for PCD,
probably because their mechanism of action is too
slow compared with the aggressiveness of the im-
mune reaction against the Purkinje cells of the cere-
bellum in the majority of these patients. A rapid
abrogation of this immune attack against the ner-
vous system could in theory be achieved with proto-
cols of autologous stem-cell transplantation. This
therapy is currently under evaluation in several ag-
gressive autoimmune disorders.10 In selected pa-
tients with anti-Yo–associated PCD (those younger
than 60 years, with no evidence of tumor, and who
are ambulatory) the efficacy of autologous stem-cell
transplantation could be considered in the setting of
a controlled protocol. In patients with more indolent
neurologic symptoms, a less aggressive immunosup-
pression should be attempted on the basis of experi-
mental evidence supporting an immunopathogenesis
for PCD. Although theoretically, immunosuppression
could exacerbate tumor growth, we did not find that
to be the case, and, as occurred in anti-Hu–associ-
ated paraneoplastic encephalomyelitis,5 treatment
with several immunotherapies was not found to be
an adverse prognostic factor for survival.
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Figure. Kaplan-Meier survival curves for 25 patients with
paraneoplastic cerebellar degeneration who received anti-
neoplastic treatment. Solid line indicates breast cancer;
dotted line, gynecologic cancer.
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